INSM•benzinga•
Insmed's TPIP Demonstrates Statistically Significant 35% Reduction In Pulmonary Vascular Resistance And 35.5-Meter Improvement In Six-Minute Walk Distance In Phase 2 Study, Shows Sustained 24-Hour Benefits And Well Tolerated With 75% Patients Reaching Hig
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 10, 2025 by benzinga